|Bid||30.10 x 900|
|Ask||35.00 x 800|
|Day's Range||31.61 - 32.98|
|52 Week Range||24.45 - 43.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.40|
Medicines Company (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pre-market, WallStEquities.com takes a look at the recent performance of Mylan N.V. (NASDAQ: MYL), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), SCYNEXIS Inc. (NASDAQ: SCYX), and The Medicines Co. (NASDAQ: MDCO). On Wednesday, shares in Canonsburg, Pennsylvania headquartered Mylan N.V. recorded a trading volume of 3.81 million shares.
The Medicines Company (MDCO) today announced that the results of a pre-specified analysis of secondary endpoints from the ORION-1 Phase II study were presented at the 86th European Atherosclerosis Society Congress (EAS 2018) and accepted for publication in Circulation, the journal of the American Heart Association. Investigators examined inclisiran’s effects beyond LDL-C and showed that it also reduces atherogenic lipoproteins in a profound and sustained manner. Atherogenic lipoproteins – non-HDL-C, ApoB, VLDL-C and Lp(a) – have each been associated with an increased risk of heart attacks and strokes, particularly in high-risk patients.
LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on Ironwood Pharma, Inc. (IRWD). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=IRWD as the Company's latest news hit the wire. On May 01, 2018, the Company declared that its Board of Directors has approved an intent to separate into two independent, publicly-traded Companies, i.e.
The Medicines Company presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association 2018 Scientific Sessions held in Las Vegas, NV.
The Medicines Company (MDCO) incurs wider-than-expected loss in the first quarter of 2018. The top line also missed estimates and declined year over year.
The Parsippany, New Jersey-based company said it had net income of 39 cents per share. Losses, adjusted for one-time gains and costs, came to 76 cents per share. The results did not meet Wall Street expectations. ...
NEW YORK, NY / ACCESSWIRE / April 25, 2018 / Medicines Company (NASDAQ: MDCO ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 25, 2018 at 8:30:00 AM Eastern Time. ...
The Medicines Company will host a conference call and audio webcast on Wednesday, April 25, 2018, at 8:30 a.m., Eastern Time, to discuss first-quarter 2018 financial results and operational developments.
Ironwood Pharmaceuticals told shareholders Monday that it's learned biotech activist investor Alex Denner of Sarissa Capital is seeking to join its board.
The Medicines Company today announced the appointment of Christopher Visioli as Chief Financial Officer and Treasurer of the Company, effective immediately. Mr. Visioli succeeds William B.
The Medicines Company (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
But what is clear is that in the not too distant future, PCSK9 inhibitors will be priced in a way that will be palatable to payers thereby making this class of important drugs available to those whose lives can be saved or prolonged by them.
The Medicines Company today announced that it will participate in the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018, in New York City, NY. The Company is scheduled to present at 08:00 a.m., Eastern Time.
Esperion popped Monday after a study from Regeneron and Sanofi validated the long-term benefits of lowering LDL cholesterol.